Clinical pharmacology of polyestradiol phosphate

@article{Gunnarsson1988ClinicalPO,
  title={Clinical pharmacology of polyestradiol phosphate},
  author={P. Gunnarsson and B. Norl{\'e}n},
  journal={The Prostate},
  year={1988},
  volume={13}
}
  • P. Gunnarsson, B. Norlén
  • Published 1988
  • Biology, Medicine
  • The Prostate
    • The results of the present studies demonstrate that intramuscular injections of polyestradiol phosphate (PEP) produce not only considerably increased estrogen concentration in plasma but also maintain the same estrone/estradiol ratio as in normal men. 
    View on Wiley
    ncbi.nlm.nih.gov
    4 Citations
    Background Citations
    1

    Topics from this paper

    Explore Further: Topics Discussed in This Paper

    4 Citations
    Citation Type

    Citation Type

    Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin®) in prostatic cancer patients
    • 6
    Steroid phosphate esters and phosphonosteroids and their biological activities
    • 4
    Vastly extended drug release from poly(pro-17β-estradiol) materials facilitates in vitro neurotrophism and neuroprotection
    • 5
    • PDF
    Differential reaction of secretory and non‐secretory proteins in hormone‐treated dunning tumor
    • 13

    References

    SHOWING 1-7 OF 7 REFERENCES
    Treatment of prostatic carcinoma with various types of estrogen derivatives.
    • 62
    Plasma concentrations of estradiol and testosterone in single-drug polyestradiol phosphate therapy for prostatic cancer.
    • 8
    Cardiovascular follow‐up of patients with prostatic cancer treated with single‐drug polyestradiol phosphate
    • 26
    Optimal testosterone concentration for the treatment of prostatic cancer.
    • 34
    A comparison of androgen status in patients with prostatic cancer treated with oral and/or parenteral estrogens or by orchidectomy
    • 22
    Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas.
    • 65
    • PDF
    High Molecular Weight Enzyme Inhibitors. III. Polyestradiol Phosphate, a Long-acting Estrogen.
    • 23
    • PDF